This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Telix Pharmaceuticals Announces PSMA...
Business webinar announcement

Telix Pharmaceuticals Announces PSMA Therapy Webinar

Analysis based on 6 articles · First reported Apr 27, 2026 · Last updated Apr 28, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of this webinar by Telix Pharmaceuticals could generate positive market sentiment for the company, as it highlights its advancements in prostate cancer therapy. The presentation of data on TLX597-Tx by Professor Louise Emmett may attract investor interest in Telix Pharmaceuticals' product pipeline.

pharmaceuticals biotechnology
Event Summary

Telix Pharmaceuticals Limited announced an educational webinar to be held on April 29-30, 2026, focusing on PSMA-targeted radionuclide therapy and its multi-product strategy for prostate cancer treatment. Dr. David N. Cade, Telix Pharmaceuticals' Group Chief Medical Officer, will host the discussion with Professor Louise Emmett from St Vincent s Hospital, Sydney. Professor Emmett will present data from her OPTIMAL-PSMA trial of TLX597-Tx, Telix Pharmaceuticals' second-generation small molecule candidate. This event aims to explore the evolution of PSMA therapy and Telix Pharmaceuticals' approach to facilitating patient access to lutetium therapy.

Entities Involved
stock
Telix Pharmaceuticals
Telix Pharmaceuticals is hosting an educational webinar to discuss its PSMA-targeted radionuclide therapy and multi-product approach to treating prostate cancer, which could positively impact its market position and future product development.
Importance 100.0 Sentiment 10.0
oth
TLX597-Tx
TLX597-Tx is Telix Pharmaceuticals' novel second-generation small molecule candidate for lutetium therapy, and its data will be showcased at the webinar, potentially increasing interest in Telix Pharmaceuticals' pipeline.
Importance 70.0 Sentiment 10.0
per
Louise Emmett
Professor Louise Emmett will discuss effective PSMA-targeted therapy and present data from her OPTIMAL-PSMA trial of TLX597-Tx, a Telix Pharmaceuticals candidate, which could influence the perception of Telix Pharmaceuticals' product.
Importance 60.0 Sentiment 0.0
per
David N. Cade
David N. Cade, Telix Pharmaceuticals Group Chief Medical Officer, will host the webinar, highlighting his role in the company's medical strategy.
Importance 50.0 Sentiment 0.0
oth
St Vincent s Hospital, Sydney
St Vincent s Hospital, Sydney is where Professor Louise Emmett serves as Director of Theranostics and Nuclear Medicine, providing a credible institutional affiliation for her presentation.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.